more

Zogenix, Inc. (ZGNX)

(Delayed Data from NSDQ)

$38.02 USD

-0.18 (-0.47%)

Updated May 3, 2019 04:00 PM ET

After-Market: $38.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zogenix (ZGNX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on November 07,2019

Zogenix (ZGNX) delivered earnings and revenue surprises of 9.52% and -42.73%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ZGNXNegative Net Change

Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study

by Zacks Equity Research Published on May 27,2019

Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.

pharmaceuticals

Options Traders Expect Huge Moves in Zogenix (ZGNX) Stock

by Zacks Equity Research Published on April 10,2019

Investors need to pay close attention to Zogenix (ZGNX) stock based on the movements in the options market lately.

ZGNXNegative Net Change

medical

Zogenix Gets Refusal to File Letter From FDA for Seizure Drug

by Zacks Equity Research Published on April 09,2019

Zogenix (ZGNX) receives a Refusal to File letter from the FDA regarding its NDA for Fintepla for the treatment of seizures associated with Dravet syndrome.

pharmaceuticals

Zogenix Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research Published on October 18,2018

Zogenix has been struggling lately, but the selling pressure may be coming to an end soon.

ZGNXNegative Net Change

pharmaceuticals

Zogenix (ZGNX) in Focus: Stock Moves 9.8% Higher

by Zacks Equity Research Published on July 16,2018

Zogenix (ZGNX) was a big mover last session, as the company saw its shares rise nearly 10% on the day.

Zogenix's Epilepsy Candidate Successful in Phase III Study

by Zacks Equity Research Published on July 13,2018

Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.

Are Options Traders Betting on a Big Move in Zogenix (ZGNX) Stock?

by Zacks Equity Research Published on June 19,2018

Investors in Zogenix (ZGNX) need to pay close attention to the stock based on moves in the options market lately.

ZGNXNegative Net Change

Why Earnings Season Could Be Great for Zogenix (ZGNX)

by Zacks Equity Research Published on March 05,2018

Zogenix (ZGNX) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.